{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:47:15Z","timestamp":1794307635651,"version":"4.9.0"},"reference-count":37,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,3,25]]},"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the prevalence and secular trends in benzodiazepine (BZD) prescribing in the Irish paediatric population. In addition, we examine coprescribing of antiepileptic, antipsychotic, antidepressant and psychostimulants in children receiving BZD drugs and compare BZD prescribing in Ireland to that in other European countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Data were obtained from the Irish General Medical Services (GMS) scheme pharmacy claims database from the Health Service Executive (HSE)\u2014Primary Care Reimbursement Services (PCRS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Children aged 0\u201315\u2005years, on the HSE-PCRS database between January 2002 and December 2011, were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>Prescribing rates were reported over time (2002\u20132011) and duration (\u2264 or &gt;90\u2005days). Age (0\u20134, 5\u201311, 12\u201315) and gender trends were established. Rates of concomitant prescriptions for antiepileptic, antipsychotics, antidepressants and psychostimulants were reported. European prescribing data were retrieved from the literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Rates decreased from 2002 (8.56\/1000 GMS population: 95% CI 8.20 to 8.92) to 2011 (5.33\/1000 GMS population: 95% CI 5.10 to 5.55). Of those children currently receiving a BZD prescription, 6% were prescribed BZD for &gt;90\u2005days. Rates were higher for boys in the 0\u20134 and 5\u201311 age ranges, whereas for girls they were higher in the 12\u201315 age groups. A substantial proportion of children receiving BZD drugs are also prescribed antiepileptic (27%), antidepressant (11%), antipsychotic (5%) and psychostimulant (2%) medicines. Prescribing rates follow a similar pattern to that in other European countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While BZD prescribing trends have decreased in recent years, this study shows that a significant proportion of the GMS children population are being prescribed BZD in the long term. This study highlights the need for guidelines for BZD prescribing in children in terms of clinical indication and responsibility, coprescribing, dosage and duration of treatment.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2014-007070","type":"journal-article","created":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T20:06:43Z","timestamp":1433966803000},"page":"e007070","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Benzodiazepine prescribing in children under 15\u2005years of age receiving free medical care on the General Medical Services scheme\u00a0in Ireland"],"prefix":"10.1136","volume":"5","author":[{"given":"K","family":"O'Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Reulbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Motterlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,6,9]]},"reference":[{"key":"2024051513215392000_5.6.e007070.1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00228-004-0765-9","article-title":"Increased psychotropic drug consumption by children in the Netherlands during 1995\u20132001 is caused by increased use of methylphenidate by boys","volume":"60","author":"Hugtenburg","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"2024051513215392000_5.6.e007070.2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-1546"},{"key":"2024051513215392000_5.6.e007070.3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1753-2000-2-26","article-title":"A three-country comparison of psychotropic medication prevalence in youth","volume":"25","author":"Zito","year":"2008","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"2024051513215392000_5.6.e007070.4","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2004.050468"},{"key":"2024051513215392000_5.6.e007070.5","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-005-2982-5"},{"key":"2024051513215392000_5.6.e007070.6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2165\/00002018-200326150-00004","article-title":"Rise in psychotropic drug prescribing in children in the UK: an urgent public health issue","volume":"26","author":"Wong","year":"2003","journal-title":"Drug Saf"},{"key":"2024051513215392000_5.6.e007070.7","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.6.679"},{"key":"2024051513215392000_5.6.e007070.8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/09540260220132653","article-title":"The pharmacological treatment of childhood anxiety disorders","volume":"14","author":"Walkup","year":"2002","journal-title":"Int Rev Psychiatry"},{"key":"2024051513215392000_5.6.e007070.9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/13651500903447810","article-title":"Usage of benzodiazepines: a review","volume":"14","author":"Donoghue","year":"2010","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2024051513215392000_5.6.e007070.10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.addbeh.2010.09.003","article-title":"Psychotropic medication history of inpatient adolescents\u2014is there a rationale for benzodiazepine prescription?","volume":"36","author":"Ilom\u00e4ki","year":"2011","journal-title":"Addict Behav"},{"key":"2024051513215392000_5.6.e007070.11","first-page":"299","article-title":"Successful clonazepam treatment of adolescents with panic disorder","volume":"8","author":"Kutcher","year":"1988","journal-title":"J Clin Psychopharmacol"},{"key":"2024051513215392000_5.6.e007070.12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/070674378703200712","article-title":"Alprazolam effects in children with anxiety disorders","volume":"32","author":"Simeon","year":"1987","journal-title":"Can J Psychiatry"},{"key":"2024051513215392000_5.6.e007070.13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004583-199201000-00006","article-title":"Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders","volume":"31","author":"Simeon","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2024051513215392000_5.6.e007070.14","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199403000-00011"},{"key":"2024051513215392000_5.6.e007070.15","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-199009000-00016","article-title":"Comparative studies of pharmacotherapy for school refusal","volume":"29","author":"Bernstein","year":"1990","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2024051513215392000_5.6.e007070.16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1528-1167.2009.02331.x","article-title":"Comparison of antiepileptic drug prescribing in children in three European countries","volume":"51","author":"Hsia","year":"2010","journal-title":"Epilepsia"},{"issue":"(Suppl 2)","key":"2024051513215392000_5.6.e007070.17","first-page":"28","article-title":"Benzodiazepine use, abuse, and dependence","volume":"66","author":"O'Brien","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"2024051513215392000_5.6.e007070.18","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200206000-00009"},{"key":"2024051513215392000_5.6.e007070.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6177(03)00096-9"},{"key":"2024051513215392000_5.6.e007070.20","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(91)90024-5"},{"key":"2024051513215392000_5.6.e007070.21","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012. Oslo, 2011."},{"key":"2024051513215392000_5.6.e007070.22","unstructured":"Benzodiazepine Committee. Report of the Benzodiazepine Committee, August 2002. Dublin: Department of Health and Children, 2002."},{"key":"2024051513215392000_5.6.e007070.23","unstructured":"Galvin B . Use of minor tranquillisers and sedatives in the WRDTF area. Drugnet Ireland, Issue 30, Summer 2009:10\u201311."},{"key":"2024051513215392000_5.6.e007070.24","unstructured":"The College of Psychiatry of Ireland. A consensus statement on the use of Benzodiazepines in specialist mental health services. Dublin. Council of the College of Psychiatry of Ireland; 2012."},{"key":"2024051513215392000_5.6.e007070.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03340060045024"},{"key":"2024051513215392000_5.6.e007070.26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/acps.12155","article-title":"Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark","volume":"129","author":"Steinhausen","year":"2014","journal-title":"Acta Psychiatr Scand"},{"key":"2024051513215392000_5.6.e007070.27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-9-72"},{"key":"2024051513215392000_5.6.e007070.28","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100279"},{"key":"2024051513215392000_5.6.e007070.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(03)00040-6"},{"key":"2024051513215392000_5.6.e007070.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2009.06.002"},{"key":"2024051513215392000_5.6.e007070.31","doi-asserted-by":"publisher","DOI":"10.3109\/08039488.2011.644809"},{"key":"2024051513215392000_5.6.e007070.32","doi-asserted-by":"publisher","DOI":"10.1542\/peds.108.2.e25"},{"key":"2024051513215392000_5.6.e007070.33","doi-asserted-by":"crossref","unstructured":"Furukawa TA , Streiner DL , Young LT . Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev 2002;(1):CD001026.","DOI":"10.1002\/14651858.CD001026"},{"key":"2024051513215392000_5.6.e007070.34","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2010.540279"},{"key":"2024051513215392000_5.6.e007070.35","doi-asserted-by":"crossref","first-page":"966","DOI":"10.4088\/JCP.v68n0622","article-title":"Pharmacoepidemiology: recent findings and challenges for child and adolescent psychopharmacology","volume":"68","author":"Zito","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"2024051513215392000_5.6.e007070.36","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2011.300477"},{"key":"2024051513215392000_5.6.e007070.37","doi-asserted-by":"publisher","DOI":"10.1257\/000282803322655563"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2014-007070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T20:41:41Z","timestamp":1715805701000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2014-007070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,9]]},"published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1136\/bmjopen-2014-007070"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2014-007070","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}